Erythropoietin Drug - Global Market Outlook (2016-2022)

  • ID: 4428362
  • Report
  • Region: Global
  • 132 pages
  • Stratistics Market Research Consulting Pvt Ltd
1 of 4

FEATURED COMPANIES

  • 3SBio Inc.
  • Amgen Inc
  • F. Hoffmann-La Roche AG
  • Hospira, Inc.
  • Intas Pharmaceuticals
  • Johnson and Johnson
  • MORE
According to MRC, the Global Erythropoietin Drug Market is accounted for $8.04 billion in 2016 and is expected to reach $14.4 billion by 2022 growing at a CAGR of 10.2% from 2016 to 2022. Rising number of chronic kidney diseases (CKD) and dialysis patient pools are the major drivers for the market. Moreover, increasing cases of cancer, HIV‘s and ESRD (End Stage Renal Diseases) are some of the factors enhancing the market growth. However, growing competition from substitute drugs and rising threats from thrombosis and PRCA are the factors inhibiting the market size.

By Application, anemia segment leads the Erythropoietin Drugs market during the forecast period. On the other hand, retail pharmacies in end user segment dominated the global market with a huge market share. In terms of geography, Europe commanded the maximum market share and will continue to dominate the market over the forecast period.

Some of the key players in the market include Johnson and Johnson, Hospira, Inc., F. Hoffmann-La Roche AG, Amgen Inc, Kyowa Hakk-Kirin Co., Ltd, 3SBi-Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, JCR Pharmaceuticals, LG Life Science, Novartis AG, Shenyang Sunshine Pharmaceutical, Sihuan Pharmaceutical, Uni-Bi-Science, Wanbang Biochemical Pharmaceuticals, Pfizer Inc., Chugai Pharmaceutical and Dragon Pharma.

Products Covered:
  • Biosimilars
  • Epoetin-Alfa
  • Epoetin-Beta
  • Darbepoietin-Alfa
  • Other Biosimilar Products
  • Biologics
  • Epoetin-Zeta
  • Epoetin-Omega
  • Other Biologic Products
Drugs Covered:
  • Biosimilar Drug
  • Xue Da Sheng
  • HEMAX
  • Abseamed
  • Retacrit
  • Epoetin-alfa BS
  • EPIA-
  • Binocrit
  • Other Biosimilar Drugs
  • Biologic Drug
  • Aranesp
  • Mircera
  • Procrit
  • NeoRecromon
  • Eprex
  • Epogen
  • Other Biologic Drugs
Applications Covered:
  • Anemia
  • HIV
  • End Stage Renal Disease
  • Cancer
  • Dialysis
  • Oncology Diseases
  • Other Applications
End Users Covered:
  • Retail Pharmacies
  • Hospital
  • Other End Users
Regions Covered:
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Italy
  • UK
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • Rest of Asia Pacific
  • Rest of the World
  • Middle East
  • Brazil
  • Argentina
  • South Africa
  • Egypt
What The Report Offers:
  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBio Inc.
  • Amgen Inc
  • F. Hoffmann-La Roche AG
  • Hospira, Inc.
  • Intas Pharmaceuticals
  • Johnson and Johnson
  • MORE
1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
4.0 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Erythropoietin Drug Market, By Product
5.1 Introduction
5.2 Biosimilars
5.2.1 Epoetin-Alfa
5.2.2 Epoetin-Beta
5.2.3 Darbepoietin-Alfa
5.2.4 Other Biosimilar Products
5.3 Biologics
5.3.1 Epoetin-Zeta
5.3.2 Epoetin-Omega
5.3.3 Other Biologic Products

6 Global Erythropoietin Drug Market, By Drug
6.1 Introduction
6.2 Biosimilar Drug
6.2.1 Xue Da Sheng
6.2.2 HEMAX
6.2.3 Abseamed
6.2.4 Retacrit
6.2.5 Epoetin-alfa BS
6.2.6 EPIAO
6.2.7 Binocrit
6.2.8 Other Biosimilar Drugs
6.3 Biologic Drug
6.3.1 Aranesp
6.3.2 Mircera
6.3.3 Procrit
6.3.4 NeoRecromon
6.3.5 Eprex
6.3.6 Epogen
6.3.7 Other Biologic Drugs

7 Global Erythropoietin Drug Market, By Application
7.1 Introduction
7.2 Anemia
7.3 HIV
7.4 End Stage Renal Disease
7.5 Cancer
7.6 Dialysis
7.7 Oncology Diseases
7.8 Other Applications

8 Global Erythropoietin Drug Market, By End User
8.1 Introduction
8.2 Retail Pharmacies
8.3 Hospital
8.4 Other End Users

9 Global Erythropoietin Drug Market, By Geography
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Johnson and Johnson
11.2 Hospira, Inc.
11.3 F. Hoffmann-La Roche AG
11.4 Amgen Inc
11.5 Kyowa Hakko Kirin Co., Ltd
11.6 3SBio Inc.
11.7 Boehringer Ingelheim Pharmaceuticals, Inc.
11.8 Intas Pharmaceuticals
11.9 Dr. Reddy's Laboratories
11.10 Teva Pharmaceutical Industries
11.11 JCR Pharmaceuticals
11.12 LG Life Science
11.13 Novartis AG
11.14 Shenyang Sunshine Pharmaceutical
11.15 Sihuan Pharmaceutical
11.16 Uni-Bio Science
11.17 Wanbang Biochemical Pharmaceuticals
11.18 Pfizer Inc.
11.19 Chugai Pharmaceutical
11.20 Dragon Pharma

List of Tables

Table 1 Global Erythropoietin Drug Market Outlook, By Region (2014-2022) ($MN)
Table 2 Global Erythropoietin Drug Market Outlook, By Product (2014-2022) ($MN)
Table 3 Global Erythropoietin Drug Market Outlook, By Biosimilars (2014-2022) ($MN)
Table 4 Global Erythropoietin Drug Market Outlook, By Epoetin-Alfa (2014-2022) ($MN)
Table 5 Global Erythropoietin Drug Market Outlook, By Epoetin-Beta (2014-2022) ($MN)
Table 6 Global Erythropoietin Drug Market Outlook, By Darbepoietin-Alfa (2014-2022) ($MN)
Table 7 Global Erythropoietin Drug Market Outlook, By Other Biosimilar Products (2014-2022) ($MN)
Table 8 Global Erythropoietin Drug Market Outlook, By Biologics (2014-2022) ($MN)
Table 9 Global Erythropoietin Drug Market Outlook, By Epoetin-Zeta (2014-2022) ($MN)
Table 10 Global Erythropoietin Drug Market Outlook, By Epoetin-Omega (2014-2022) ($MN)
Table 11 Global Erythropoietin Drug Market Outlook, By Other Biologic Products (2014-2022) ($MN)
Table 12 Global Erythropoietin Drug Market Outlook, By Drug (2014-2022) ($MN)
Table 13 Global Erythropoietin Drug Market Outlook, By Biosimilar Drug (2014-2022) ($MN)
Table 14 Global Erythropoietin Drug Market Outlook, By Xue Da Sheng (2014-2022) ($MN)
Table 15 Global Erythropoietin Drug Market Outlook, By HEMAX (2014-2022) ($MN)
Table 16 Global Erythropoietin Drug Market Outlook, By Abseamed (2014-2022) ($MN)
Table 17 Global Erythropoietin Drug Market Outlook, By Retacrit (2014-2022) ($MN)
Table 18 Global Erythropoietin Drug Market Outlook, By Epoetin-alfa BS (2014-2022) ($MN)
Table 19 Global Erythropoietin Drug Market Outlook, By EPIAO (2014-2022) ($MN)
Table 20 Global Erythropoietin Drug Market Outlook, By Binocrit (2014-2022) ($MN)
Table 21 Global Erythropoietin Drug Market Outlook, By Other Biosimilar Drugs (2014-2022) ($MN)
Table 22 Global Erythropoietin Drug Market Outlook, By Biologic Drug (2014-2022) ($MN)
Table 23 Global Erythropoietin Drug Market Outlook, By Aranesp (2014-2022) ($MN)
Table 24 Global Erythropoietin Drug Market Outlook, By Mircera (2014-2022) ($MN)
Table 25 Global Erythropoietin Drug Market Outlook, By Procrit (2014-2022) ($MN)
Table 26 Global Erythropoietin Drug Market Outlook, By NeoRecromon (2014-2022) ($MN)
Table 27 Global Erythropoietin Drug Market Outlook, By Eprex (2014-2022) ($MN)
Table 28 Global Erythropoietin Drug Market Outlook, By Epogen (2014-2022) ($MN)
Table 29 Global Erythropoietin Drug Market Outlook, By Other Biologic Durgs (2014-2022) ($MN)
Table 30 Global Erythropoietin Drug Market Outlook, By Application (2014-2022) ($MN)
Table 31 Global Erythropoietin Drug Market Outlook, By Anemia (2014-2022) ($MN)
Table 32 Global Erythropoietin Drug Market Outlook, By HIV (2014-2022) ($MN)
Table 33 Global Erythropoietin Drug Market Outlook, By End Stage Renal Disease (2014-2022) ($MN)
Table 34 Global Erythropoietin Drug Market Outlook, By Cancer (2014-2022) ($MN)
Table 35 Global Erythropoietin Drug Market Outlook, By Dialysis (2014-2022) ($MN)
Table 36 Global Erythropoietin Drug Market Outlook, By Oncology Diseases (2014-2022) ($MN)
Table 37 Global Erythropoietin Drug Market Outlook, By Other Applications (2014-2022) ($MN)
Table 38 Global Erythropoietin Drug Market Outlook, By End User (2014-2022) ($MN)
Table 39 Global Erythropoietin Drug Market Outlook, By Retail Pharmacies (2014-2022) ($MN)
Table 40 Global Erythropoietin Drug Market Outlook, By Hospital (2014-2022) ($MN)
Table 41 Global Erythropoietin Drug Market Outlook, By Other End Users (2014-2022) ($MN)
Table 42 North America Erythropoietin Drug Market Outlook, By Country (2014-2022) ($MN)
Table 43 North America Erythropoietin Drug Market Outlook, By Product (2014-2022) ($MN)
Table 44 North America Erythropoietin Drug Market Outlook, By Biosimilars (2014-2022) ($MN)
Table 45 North America Erythropoietin Drug Market Outlook, By Epoetin-Alfa (2014-2022) ($MN)
Table 46 North America Erythropoietin Drug Market Outlook, By Epoetin-Beta (2014-2022) ($MN)
Table 47 North America Erythropoietin Drug Market Outlook, By Darbepoietin-Alfa (2014-2022) ($MN)
Table 48 North America Erythropoietin Drug Market Outlook, By Other Biosimilar Products (2014-2022) ($MN)
Table 49 North America Erythropoietin Drug Market Outlook, By Biologics (2014-2022) ($MN)
Table 50 North America Erythropoietin Drug Market Outlook, By Epoetin-Zeta (2014-2022) ($MN)
Table 51 North America Erythropoietin Drug Market Outlook, By Epoetin-Omega (2014-2022) ($MN)
Table 52 North America Erythropoietin Drug Market Outlook, By Other Biologic Products (2014-2022) ($MN)
Table 53 North America Erythropoietin Drug Market Outlook, By Drug (2014-2022) ($MN)
Table 54 North America Erythropoietin Drug Market Outlook, By Biosimilar Drug (2014-2022) ($MN)
Table 55 North America Erythropoietin Drug Market Outlook, By Xue Da Sheng (2014-2022) ($MN)
Table 56 North America Erythropoietin Drug Market Outlook, By HEMAX (2014-2022) ($MN)
Table 57 North America Erythropoietin Drug Market Outlook, By Abseamed (2014-2022) ($MN)
Table 58 North America Erythropoietin Drug Market Outlook, By Retacrit (2014-2022) ($MN)
Table 59 North America Erythropoietin Drug Market Outlook, By Epoetin-alfa BS (2014-2022) ($MN)
Table 60 North America Erythropoietin Drug Market Outlook, By EPIAO (2014-2022) ($MN)
Table 61 North America Erythropoietin Drug Market Outlook, By Binocrit (2014-2022) ($MN)
Table 62 North America Erythropoietin Drug Market Outlook, By Other Biosimilar Drugs (2014-2022) ($MN)
Table 63 North America Erythropoietin Drug Market Outlook, By Biologic Drug (2014-2022) ($MN)
Table 64 North America Erythropoietin Drug Market Outlook, By Aranesp (2014-2022) ($MN)
Table 65 North America Erythropoietin Drug Market Outlook, By Mircera (2014-2022) ($MN)
Table 66 North America Erythropoietin Drug Market Outlook, By Procrit (2014-2022) ($MN)
Table 67 North America Erythropoietin Drug Market Outlook, By NeoRecromon (2014-2022) ($MN)
Table 68 North America Erythropoietin Drug Market Outlook, By Eprex (2014-2022) ($MN)
Table 69 North America Erythropoietin Drug Market Outlook, By Epogen (2014-2022) ($MN)
Table 70 North America Erythropoietin Drug Market Outlook, By Other Biologic Durgs (2014-2022) ($MN)
Table 71 North America Erythropoietin Drug Market Outlook, By Application (2014-2022) ($MN)
Table 72 North America Erythropoietin Drug Market Outlook, By Anemia (2014-2022) ($MN)
Table 73 North America Erythropoietin Drug Market Outlook, By HIV (2014-2022) ($MN)
Table 74 North America Erythropoietin Drug Market Outlook, By End Stage Renal Disease (2014-2022) ($MN)
Table 75 North America Erythropoietin Drug Market Outlook, By Cancer (2014-2022) ($MN)
Table 76 North America Erythropoietin Drug Market Outlook, By Dialysis (2014-2022) ($MN)
Table 77 North America Erythropoietin Drug Market Outlook, By Oncology Diseases (2014-2022) ($MN)
Table 78 North America Erythropoietin Drug Market Outlook, By Other Applications (2014-2022) ($MN)
Table 79 North America Erythropoietin Drug Market Outlook, By End User (2014-2022) ($MN)
Table 80 North America Erythropoietin Drug Market Outlook, By Retail Pharmacies (2014-2022) ($MN)
Table 81 North America Erythropoietin Drug Market Outlook, By Hospital (2014-2022) ($MN)
Table 82 North America Erythropoietin Drug Market Outlook, By Other End Users (2014-2022) ($MN)
Table 83 Europe Erythropoietin Drug Market Outlook, By Country (2014-2022) ($MN)
Table 84 Europe Erythropoietin Drug Market Outlook, By Product (2014-2022) ($MN)
Table 85 Europe Erythropoietin Drug Market Outlook, By Biosimilars (2014-2022) ($MN)
Table 86 Europe Erythropoietin Drug Market Outlook, By Epoetin-Alfa (2014-2022) ($MN)
Table 87 Europe Erythropoietin Drug Market Outlook, By Epoetin-Beta (2014-2022) ($MN)
Table 88 Europe Erythropoietin Drug Market Outlook, By Darbepoietin-Alfa (2014-2022) ($MN)
Table 89 Europe Erythropoietin Drug Market Outlook, By Other Biosimilar Products (2014-2022) ($MN)
Table 90 Europe Erythropoietin Drug Market Outlook, By Biologics (2014-2022) ($MN)
Table 91 Europe Erythropoietin Drug Market Outlook, By Epoetin-Zeta (2014-2022) ($MN)
Table 92 Europe Erythropoietin Drug Market Outlook, By Epoetin-Omega (2014-2022) ($MN)
Table 93 Europe Erythropoietin Drug Market Outlook, By Other Biologic Products (2014-2022) ($MN)
Table 94 Europe Erythropoietin Drug Market Outlook, By Drug (2014-2022) ($MN)
Table 95 Europe Erythropoietin Drug Market Outlook, By Biosimilar Drug (2014-2022) ($MN)
Table 96 Europe Erythropoietin Drug Market Outlook, By Xue Da Sheng (2014-2022) ($MN)
Table 97 Europe Erythropoietin Drug Market Outlook, By HEMAX (2014-2022) ($MN)
Table 98 Europe Erythropoietin Drug Market Outlook, By Abseamed (2014-2022) ($MN)
Table 99 Europe Erythropoietin Drug Market Outlook, By Retacrit (2014-2022) ($MN)
Table 100 Europe Erythropoietin Drug Market Outlook, By Epoetin-alfa BS (2014-2022) ($MN)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Johnson and Johnson
  • Hospira, Inc.
  • F. Hoffmann-La Roche AG
  • Amgen Inc
  • Kyowa Hakko Kirin Co., Ltd
  • 3SBio Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Intas Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll